keyword
MENU ▼
Read by QxMD icon Read
search

Haploidentical transplant

keyword
https://www.readbyqxmd.com/read/28108270/hla-haploidentical-transplantation-for-relapsed-refractory-hodgkin-lymphoma-a-multicentre-analysis
#1
Marcelo Pitombeira de Lacerda, Celso Arrais Rodrigues, André Domingues Pereira, Yana Novis, Marina Fonseca, Roberto L Silva, Maria C M A Macedo, Nelson Hamerschlak, Iracema Esteves, Jayr Schmidt Filho, Marina M Nascimento, Vanderson Rocha
Reduced-intensity conditioning, allogeneic stem cell transplantation remains a potentially curative approach for relapsed/refractory Hodgkin Lymphoma (HL) relapsing after an autologous SCT. In the absence of a HLA-identical donor, haploidentical SCT (haplo-SCT) with posttransplant cyclophosphamide (PT-Cy) has been evaluated with favorable preliminary results. We evaluated 24 patients who underwent a haplo-SCT for relapsed/refractory HL. Conditioning regimen consisted of cyclophosphamide, fludarabine and TBI, and GVHD prophylaxis consisted of a calcineurin inhibitor, mycophenolate mofetil and PT-Cy (50mg/kg/day for 2 days) for all patients...
January 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28107815/upfront-haploidentical-transplant-for-acquired-severe-aplastic-anemia-registry-based-comparison-with-matched-related-transplant
#2
Lan-Ping Xu, Song Jin, Shun-Qing Wang, Ling-Hui Xia, Hai Bai, Su-Jun Gao, Qi-Fa Liu, Jian-Min Wang, Xin Wang, Ming Jiang, Xi Zhang, De-Pei Wu, Xiao-Jun Huang
BACKGROUND: Haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT) is an alternative treatment method for severe aplastic anemia (SAA) patients lacking suitable identical donors and those who are refractory to immunosuppressive therapy (IST). The current study evaluated the feasibility of upfront haploidentical HSCT in SAA patients. METHODS: We conducted a multicenter study based on a registry database. One hundred fifty-eight SAA patients who underwent upfront transplantation between June 2012 and September 2015 were enrolled...
January 21, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28104146/successful-rescue-of-late-onset-antibody-mediated-rejection-12-years-after-living-donor-intestinal-transplantation-a-case-report
#3
G S Wu, Q C Zhao, Z S Li, Y Wu, W Z Wang, M B Li, H Shi, M Wang, D L Chen, J Y Zheng, X Wang, D M Fan
BACKGROUND: Antibody-mediated rejection (ABMR) has recently surfaced as a potential form of graft dysfunction after intestinal transplantation. METHODS: We present a case of an intestinal transplant recipient who developed late-onset ABMR 12 years after living-donor transplantation. An 18-year-old male recipient with a history of extensive intestinal resection secondary to acute bowel volvulus exhibited an excellent baseline immune profile for transplantation, including ABO-identical and HLA-haploidentical to the donor; a negative cross-match with a panel reactive antibody of 3...
January 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28103944/a-comparison-between-allogeneic-stem-cell-transplantation-from-unmanipulated-haploidentical-and-unrelated-donors-in-acute-leukemia
#4
Simona Piemontese, F Ciceri, M Labopin, W Arcese, S Kyrcz-Krzemien, S Santarone, H Huang, D Beelen, N C Gorin, C Craddock, Z Gulbas, A Bacigalupo, M Mohty, A Nagler
BACKGROUND: In the absence of a HLA-matched related or matched unrelated donor, allogeneic stem cell transplantation (allo-SCT) from mismatched unrelated donors or haploidentical donors are potential alternatives for patients with acute leukemia with an indication to allo-SCT. The objective of this study was to compare the outcome of allo-SCT from T cell-replete haploidentical (Haplo) versus matched (MUD 10/10) or mismatched unrelated donor at a single HLA-locus (MMUD 9/10) for patients with acute leukemia in remission...
January 19, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28103645/prognostic-impact-of-lymphocyte-subpopulations-in-peripheral-blood-after-hematopoietic-stem-cell-transplantation-for-hematologic-malignancies
#5
Sang Hyuk Park, Chan-Jeoung Park, Borae G Park, Mi-Hyun Bae, Bo-Hyun Kim, Young-Uk Cho, Seongsoo Jang, Ae Ja Park, Dae-Young Kim, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee
BACKGROUND: We prospectively evaluated prognostic value of lymphocyte subpopulations in peripheral blood of allogeneic hematopoietic stem cell transplant (HSCT)-recipients. METHODS: 113 allogeneic HSCT (47 sibling matched, 37 unrelated matched, 29 haploidentical)-performed patients diagnosed as AML (n=66), ALL (n=28) and MDS (n=19) were prospectively enrolled. 14 lymphocyte subpopulations were quantified by flow cytometry of PB at specific time-points after HSCT, and their prognostic impacts were analyzed...
January 19, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28092347/haploidentical-transplantation-with-post-infusion-cyclophosphamide-in-advanced-hodgkin-lymphoma
#6
L Castagna, S Bramanti, R Devillier, B Sarina, R Crocchiolo, S Furst, J E Cheikh, A Granata, C Faucher, S Harbi, L Morabito, J Mariotti, S Puvinathan, P J Weiller, C Chabannon, D Mokart, C Carlo-Stella, R Bouabdallah, A Santoro, D Blaise
We investigated the use of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of advanced Hodgkin lymphoma (HL). Sixty-two consecutive HL patients underwent haplo-HSCT. Unmanipulated stem cells and post-transplant cyclophosphamide were given to all patients as GVHD prophylaxis. At 100 days, the cumulative incidence of grades 2-3 and grades 3-4 acute GVHD was 23% and 4%, respectively. The chronic GVHD (cGVHD) cumulative incidence was 16%, with one patient experiencing severe cGVHD...
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28087457/t-cell-replete-peripheral-blood-haploidentical-hematopoietic-cell-transplantation-with-post-transplant-cyclophosphamide-results-in-outcomes-similar-to-traditionally-matched-donors-in-active-disease-acute-myeloid-leukemia
#7
Joan How, Michael Slade, Khoan Vu, John F DiPersio, Peter Westervelt, Geoffrey L Uy, Camille N Abboud, Ravi Vij, Mark A Schroeder, Todd A Fehniger, Rizwan Romee
Outcomes for acute myeloid leukemia (AML) patients who fail to achieve complete remission remain poor. Hematopoietic cell transplantation (HCT) has been shown to induce long-term survival in AML patients with active disease. HCT is largely performed with HLA-matched unrelated or HLA-matched related donors. Recently, HCT with HLA-haploidentical related donors has been identified as a feasible option when HLA-matched donors are not immediately available. However, there is little data comparing outcomes of AML patients with active disease who receive haploidentical versus traditionally matched HCT...
January 10, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28067886/dose-adapted-post-transplant-cyclophosphamide-for-hla-haploidentical-transplantation-in-fanconi-anemia
#8
M S Thakar, C Bonfim, M C Walters, R Storb, R Pasquini, L Burroughs, B M Sandmaier, A Woolfrey, H-P Kiem
We developed a haploidentical transplantation protocol with post-transplant cyclophosphamide (CY) for in vivo T-cell depletion (TCD) using a novel adapted-dosing schedule (25 mg/kg on days +3 and +4) for Fanconi anemia (FA). With median follow-up of 3 years (range, 37 days to 6.2 years), all six patients engrafted. Two patients with multiple pre-transplant comorbidities died, one from sepsis and one from sepsis with associated chronic GVHD. Four patients without preexisting comorbidities and early transplant referrals are alive with 100% donor chimerism and excellent performance status...
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28067885/acquired-uniparental-disomy-in-chromosome-6p-as-a-feature-of-relapse-after-t-cell-replete-haploidentical-hematopoietic-stem-cell-transplantation-using-cyclophosphamide-tolerization
#9
D Grosso, E Johnson, B Colombe, O Alpdogan, M Carabasi, J Filicko-O'Hara, S Gaballa, M Kasner, T Klumpp, U Martinez-Outschoorn, J L Wagner, M Weiss, Z Wang, N Flomenberg
No abstract text is available yet for this article.
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28067884/reversal-of-pre-capillary-pulmonary-hypertension-in-a-patient-with-sickle-cell-anemia-who-underwent-haploidentical-peripheral-blood-stem-cell-transplantation
#10
C Pittman, M M Hsieh, W Coles, J F Tisdale, N A Weir, C D Fitzhugh
No abstract text is available yet for this article.
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28067881/single-institution-experience-with-g-csf-mobilized-t-cell-replete-haploidentical-hematopoietic-cell-transplantation
#11
E Huselton, M Slade, J F DiPersio, P Westervelt, R Vij, G L Uy, T A Fehniger, C N Abboud, F Gao, M A Schroeder, R Romee
No abstract text is available yet for this article.
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28067878/successful-haploidentical-bmt-with-post-transplant-cyclophosphamide-for-refractory-autoimmune-pancytopenia-after-cord-blood-transplant-in-pediatric-myelodysplastic-syndrome
#12
H Shima, K Isshiki, Y Yamada, F Yamazaki, T Takahashi, H Shimada
No abstract text is available yet for this article.
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28067873/cotransplantation-of-bone-marrow-derived-mesenchymal-stem-cells-in-haploidentical-hematopoietic-stem-cell-transplantation-in-patients-with-severe-aplastic-anemia-an-interim-summary-for-a-multicenter-phase-ii-trial-results
#13
Z Liu, Y Zhang, H Xiao, Z Yao, H Zhang, Q Liu, B Wu, D Nie, Y Li, Y Pang, Z Fan, L Li, Z Jiang, F Duan, H Li, P Zhang, Y Gao, L Ouyang, C Yue, M Xie, C Shi, Y Xiao, S Wang
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for severe aplastic anemia (SAA) is mainly limited by the high incidence of graft failure and GvHD. Mesenchymal stem cells (MSCs) have been shown to support hematopoiesis in vivo and to display potent immunosuppressive effects to prevent or treat GvHD after HSCT. In a multicenter phase II trial, we developed an approach with co-transplantation of MSCs in patients undergoing haplo-HSCT. Forty-four patients with SAA were included. The conditioning regimen included busulfan, cyclophosphamide and thymoglobulin (ATG)...
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28067872/reduced-intensity-and-non-myeloablative-allogeneic-stem-cell-transplantation-from-alternative-hla-mismatched-donors-for-hodgkin-lymphoma-a-study-by-the-french-society-of-bone-marrow-transplantation-and-cellular-therapy
#14
J Gauthier, L Castagna, F Garnier, T Guillaume, G Socié, S Maury, N Maillard, R Tabrizi, T Marchand, J Malfuson, A Gac, E Gyan, M Mercier, Y Béguin, J Delage, P Turlure, A Marçais, S Nguyen, R Dulery, J Bay, A Huynh, E Daguindau, J Cornillon, C Régny, M Michallet, R Peffault de Latour, I Yakoub-Agha, D Blaise
Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with refractory/relapsed Hodgkin lymphoma (HL). When an HLA-matched donor is lacking a graft from a familial haploidentical (HAPLO) donor, a mismatched unrelated donor (MMUD) or cord blood (CB) might be considered. In this retrospective study, we compared the outcome of patients with HL undergoing a RIC or NMA allo-SCT from HAPLO, MMUD or CB...
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28058216/overview-of-the-progress-on-haploidentical-hematopoietic-transplantation
#15
REVIEW
Nosha Farhadfar, William J Hogan
Allogeneic hematopoietic stem cell transplant (HSCT) remains the only potentially curative option for variety of hematologic disorders. Lack of a suitable fully HLA-matched donor limits this option for many patients. Without a suitable related or unrelated HLA-matched donor, umbilical cord blood and haploidentical family members provide a potential source of stem cells. Timely donor availability makes haploidentical donors an attractive alternative donor source. Initial attempts at haploidentical HSCT was associated with significantly increased mortality owing to high rates of graft rejection and severe graft-versus-host disease caused by major donor-recipient HLA-disparity...
December 24, 2016: World Journal of Transplantation
https://www.readbyqxmd.com/read/28056398/clinical-outcome-of-myeloid-sarcoma-in-adult-patients-and-effect-of-allogeneic-stem-cell-transplantation-results-from-a-multicenter-survey
#16
Davide Lazzarotto, Anna Candoni, Carla Filì, Fabio Forghieri, Livio Pagano, Alessandro Busca, Giuseppina Spinosa, Maria Elena Zannier, Erica Simeone, Miriam Isola, Erika Borlenghi, Lorella Melillo, Federico Mosna, Federica Lessi, Renato Fanin
INTRODUCTION: Myeloid Sarcoma (MS) is a rare hematologic myeloid neoplasm that can involve any site of the body. It can occur as an exclusively extramedullary form or it can be associated with an acute myeloid leukemia (AML), a chronic myeloproliferative neoplasm (MPN) or a myelodysplastic syndrome (MDS) at onset or at relapse. The rarity of MS does not enable prospective clinical trials and therefore a specific multicenter register can be useful for the clinical and biological studies of this rare disease...
December 20, 2016: Leukemia Research
https://www.readbyqxmd.com/read/28054442/markers-and-function-of-human-nk-cells-in-normal-and-pathological-conditions
#17
REVIEW
Genny Del Zotto, Emanuela Marcenaro, Paola Vacca, Simona Sivori, Daniela Pende, Mariella Della Chiesa, Francesca Moretta, Tiziano Ingegnere, Maria Cristina Mingari, Alessandro Moretta, Lorenzo Moretta
Natural killer (NK) cells, the most important effectors of the Innate Lymphoid Cells (ILCs), play a fundamental role in tumor immune-surveillance, defense against viruses and, in general, in innate immune responses. NK cell activation is mediated by several activating receptors and co-receptors able to recognize ligands on virus-infected or tumor cells. To prevent healthy cells from auto-aggression, NK cells are provided with strong inhibitory receptors (KIRs and NKG2A) which recognize HLA class I molecules on target cells and, sensing their level of expression, allow killing of targets underexpressing HLA-class I...
January 5, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28039267/potent-anti-leukemia-activities-of-chimeric-antigen-receptor-modified-t-cells-against-cd19-in-chinese-patients-with-relapsed-refractory-acute-lymphocytic-leukemia
#18
Yongxian Hu, Zhao Wu, Yi Luo, Jimin Shi, Jian Yu, Chengfei Pu, Zhuyu Liang, Guoqing Wei, Qu Cui, Jie Sun, Jing Jiang, Jue Xie, Yamin Tan, Wanmao Ni, Jifang Tu, Jinping Wang, Aiyun Jin, Hao Zhang, Zhen Cai, Lei Xiao, He Huang
PURPOSE: Patients with relapsed/refractory acute lymphocytic leukemia (R/R ALL) have a poor prognosis. Chimeric antigen receptor modified T cells against CD19 (CART19s) have displayed anti-leukemia activities. However, data from systemic trials in Chinese patients are limited. STUDY DESIGN: T cells transduced with CD19-directed CAR lentiviral vectors were infused in patients with R/R ALL under fludarabine- and cyclophosphamide-based lymphodepletion. The post-infusion responses, toxicities, expansion and persistence of CART19s in enrolled patients were observed and monitored...
December 30, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28039080/risk-factors-for-and-the-clinical-impact-of-cytomegalovirus-and-epstein-barr-virus-infections-in-pediatric-recipients-of-tcr-%C3%AE-%C3%AE-and-cd19-depleted-grafts
#19
Alexandra Laberko, Anna Bogoyavlenskaya, Larisa Shelikhova, Zhanna Shekhovtsova, Dmitriy Balashov, Kirill Voronin, Elena Kurnikova, Elena Boyakova, Elena Raykina, Varvara Brilliantova, Valentina Pirumova, Galina Novichkova, Alexei Maschan, Michael Maschan
Both α/β T cell and CD19 depletion are used to improve the outcomes of hematopoietic stem cell transplantation (HSCT). We evaluated the burden of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in pediatric patients after this HSCT type. A cohort of 182 patients with malignant (n = 114) or nonmalignant (n = 68) disorders was transplanted from either matched unrelated (n = 124) or haploidentical (n = 58) donors. The cumulative incidence of CMV and EBV viremia were 51% and 33%, respectively...
December 27, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28035752/the-effect-of-mhc-antigen-matching-between-donors-and-recipients-on-skin-tolerance-of-vascularized-composite-allografts
#20
K Shanmugarajah, H Powell, D A Leonard, C Mallard, A Albritton, E Harrington, M A Randolph, E Farkash, D H Sachs, J M Kurtz, C L Cetrulo
The emergence of skin-containing vascularized composite allografts (VCAs) has provided impetus to understand factors affecting rejection/tolerance of skin. VCA tolerance can be established in miniature swine across haploidentical MHC barriers using mixed chimerism. As the deceased donor pool for VCAs does not permit MHC antigen matching, clinical VCAs are transplanted across varying MHC disparities. Here, we investigated whether sharing of MHC class I or class II antigens between donors and recipients influences VCA skin tolerance...
December 30, 2016: American Journal of Transplantation
keyword
keyword
13298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"